Recent advances in the development of P2Y14R inhibitors: a patent and literature review (2018-present).

Abstract

Introduction: The P2Y₁₄ receptor (P2Y₁₄R), a member of the G protein-coupled receptor family, is activated by extracellular nucleotides. Due to its involvement in inflammatory, immunological and other associated processes, P2Y₁₄R has emerged as a promising therapeutic target. Despite lacking a determined three-dimensional crystal structure, the homology modeling technique based on closely related P2Y receptors' crystallography has been extensively utilized for developing active compounds targeting P2Y₁₄R. Recent discoveries have unveiled numerous highly effective and subtype-specific P2Y₁₄R inhibitors. This study presents an overview of the latest advancements in P2Y₁₄R inhibitors.

Areas covered: This review presents an overview of the advancements in P2Y₁₄R inhibitor research over the past five years, encompassing new patents, journal articles, and highlighting the therapeutic prospects inherent in these compounds.

Expert opinion: The recent revelation of the vast potential of P2Y₁₄R inhibitors has led to the development of novel compounds that exhibit promising capabilities for the treatment of sterile inflammation of the kidney, potentially diabetes, and asthma. Despite being a relatively nascent class of compounds, certain members have already exhibited their capacity to surmount specific challenges posed by conventional P2Y₁₄R inhibitors. Targeting P2Y₁₄R through small molecules may present a promising therapeutic strategy for effectively managing diverse inflammatory diseases.